Health Economics›Bladder cancer›Metastatic disease, platinum-refractory

Metastatic disease, platinum-refractory

Bladder cancer · 2 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 1 point

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Durvalumab monotherapy Variant #01	—	R 61 460	14d	~15.3 mo	~16.6 mo	~34	~R 2 089 654 PFS proxy · indirect	7
Atezolizumab monotherapy Variant #01	—	R 31 255	21d	—	—	—	—	1

2 of 2 regimens shown